Senior man looking at female nurse helping him to wear sweater in retirement home (Maskot/Getty Images)
Americans 60 and older can get a new RSV vaccine but should discuss it with their doctor first, U.S. health officials recommended Thursday.
The newly approved vaccines are expected to be ready in the fall, a time when flu shots and updated COVID-19 shots also will be available. Those eligible for the RSV vaccine should talk with their doctor to see if it is right for them, the Centers for Disease Control and Prevention said in a statement.
The CDC said adults with chronic heart or lung disease, weakened immune systems and those living in long-term care facilities are at higher risk for the respiratory infection.
RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms but it can be dangerous for infants and the elderly. A surge last year filled hospitals with wheezing children. There's no vaccine yet for kids, but one for pregnant women to prevent illness in infants may be coming too, pending approval from the Food and Drug Administration.
On Thursday, Dr. Rochelle Walensky, the outgoing CDC director, signed off on a recommendation made last week by an advisory panel of outside experts for a single dose of the vaccines made by Pfizer and GSK. The FDA approved the shots last month for adults 60 and older.
The CDC panel initially considered a stronger recommendation that everyone 65 and older get the shot. But they weakened their endorsement after several members had questions about how well it works in the feeblest of patients, whether boosters will be needed and be effective, and the cost.
Drugmaker GSK told the panel that its RSV vaccine would be between $200 and $295. Pfizer has not disclosed a price. The vaccines may hold up over multiple seasons and it’s not yet clear whether boosters will be recommended.
Others wanted a stronger endorsement for those 65 and older. Asking people to consult their doctor “is an absolute impediment" to getting more people vaccinated and an extra burden on health care providers, Robert Blancato, executive director of the National Association of Nutrition and Aging Services Programs, said Thursday.
On this episode of Cheddar Innovates: Evolution Devices CEO breaks down how the Evowalk wearable device can help those with walking impairments; Cresilon CEO explains how he's created a plant-based gel to easily treat wounds in both humans and animals; A look at Curiosity Stream's 'The Colorado Problem.'
Pier Mantovani, Founder and CEO of Evolution Devices, joins Cheddar Innovates to discuss how the Evowalk wearable device can help those with walking impairments, and how remote physical therapy is becoming a reality.
Joe Landolina, CEO and Co-Founder of Cresilon, joins Cheddar Innovates to discuss how he's created a plant-based gel to easily treat wounds in both humans and animals.
A new analysis reveals that for more than two decades, the West has been the driest it has ever been since 800 A.D. The drought which began in 2000 has brought more devastating wildfires and draining water reserves well below healthy levels. Climate Scientists and Adjunct Associate Research Scientist at Lamont Doherty Earth Observatory at Columbia University,Benjamin Cook, joined Cheddar to discuss more.
Energy Vault, the company developing sustainable, grid-scale energy storage solutions, is now trading on the New York Stock Exchange following the completion of its business combination with Novus Capital Corporation II. Energy Vault develops sustainable, grid-scale energy storage solutions designed to advance the transition to a carbon free, resilient power grid. Robert Piconi, co-founder and CEO of Energy Vault, joins Cheddar News' Closing Bell to disucss.
In an effort to fight climate change several corporations have vowed to work to fight climate change by 2030. They say the goal is to reduce carbon emissions by 40% or even close to 100%. However, according to a new study, many of these companies are not actually practicing what they preach. Tom Egger, senior lecturer at Emeritus at the University of Wisconsin, joins Cheddar News to discuss more.
At-home medical labs company Getlabs raised $20 million in a Series A round, led by Emerson Collective and the Minderoo Foundation. Getlabs aims to be the boots-on-the-ground partner to telehealth. The company says more than 70% of medical decisions still require collecting diagnostic tests in person, and that it fills that void by delivering health care directly to their patients' homes. Founder & CEO of Getlabs Kyle Michelson joined Cheddar News' Closing Bell to discuss.
Kalle Marsal, Chief Operating Officer at PetDx, joins Cheddar Innovates to discuss how next-generation sequencing technology is being used to detect cancer in pets early.
On this episode of Cheddar Innovates: WALDO CEO breaks down why now is a good time to make eyecare a priority, and how they are democratizing access to eyecare for all; COO at PetDx explains how next-generation sequencing technology is being used to detect cancer in pets early; Cheddar gets a look at Curiosity Stream's 'Inside The Mind of a Con Artist.'
